Physician profile
Robert Rushton
NPI 1376503839
$1,891.92
in general payments reported to CMS, 2019-2025
16 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $266 · 2021: $590 · 2022: $445 · 2023: $72.16 · 2024: $39.35 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,003.14 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $159.84 | 2020-2025 | Zepbound |
| Glaxosmithkline, LLC. | $145.92 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Nestle Healthcare Nutrition INC. | $85.63 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $84.42 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $76.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.39 | 2020-2022 | |
| Abbott Laboratories | $74.46 | 2019-2022 | |
| Abbvie INC. | $43.23 | 2022-2023 | Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $33.95 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $22.50 | 2019 | |
| Amarin Pharma, INC. | $22.14 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.40 | 2019 | |
| Pfizer INC. | $14.78 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rushton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.